142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding

Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in type 2 diabetes mellitus (T2DM) patients. Preclinical data indicate that TZP lowers body weight due to a reduction in caloric intake; however, associated effects on feeding behavior...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2020-06, Vol.69 (Supplement_1)
Hauptverfasser: COSGROVE, RICHARD, ANTONELLIS, MEGHAN P., DROZ, BRIAN, ROELL, WILLIAM C., SLOOP, KYLE, MOYERS, JULIE, COGHLAN, MATTHEW P., EMMERSON, PAUL, COSKUN, TAMER, SAMMS, RICARDO J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title Diabetes (New York, N.Y.)
container_volume 69
creator COSGROVE, RICHARD
ANTONELLIS, MEGHAN P.
DROZ, BRIAN
ROELL, WILLIAM C.
SLOOP, KYLE
MOYERS, JULIE
COGHLAN, MATTHEW P.
EMMERSON, PAUL
COSKUN, TAMER
SAMMS, RICARDO J.
description Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in type 2 diabetes mellitus (T2DM) patients. Preclinical data indicate that TZP lowers body weight due to a reduction in caloric intake; however, associated effects on feeding behavior have not been studied. To investigate how TZP affects homeostatic feeding, we examined its effect on markers of satiation (meal size), satiety (meal frequency) and hunger (time-interval between meals) in obese mice. Chronic treatment with TZP dose-dependently lowered body weight and food intake in high-fat fed mice. This reduction in total daily caloric intake was underlined by a reduction in meal size and frequency throughout a 14-day treatment period. Indicating that TZP’s effect on total energy intake is associated with reduced hunger and increased satiety. One driver of the current obesity epidemic is the consumption of highly palatable/calorically dense foods. To determine whether the anorexigenic action of TZP is associated with reward-related feeding, we exposed lean and obese mice to two-choice diet paradigms ((low-fat (6% of kcal from fat) vs. high-fat (40% or 60% of kcal from fat) diets). Importantly, we found that while TZP decreased total calories consumed, it also altered macronutrient preference by increasing the intake of a low-fat diet and reducing intake of a high-fat diet. Furthermore, when exposed to a series of two-choice bottle tests, TZP reduced the consumption of nutritive (fructose and sucrose) and non-nutritive (sucralose) tastants, suggesting that TZP’s anorexigenic action may be linked to the taste and caloric content of food. Taken together, these data indicate that TZP’s ability to lower daily energy intake is mediated by both a reduction in homeostatic and reward-driven food intake.
doi_str_mv 10.2337/db20-142-OR
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2419451227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2419451227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c647-3e701db38663b340c9aadf652af76c04978640e70710001725cfaa0e33cee5263</originalsourceid><addsrcrecordid>eNotkU1PAjEQhhujiYie_ANNPEq1H8uW9UaQrwQC2XDwtintLCmBLbYlfvwb_6lFzBzmME-eNzOD0D2jT1wI-WzWnBKWcbIoL1CLFaIggsu3S9SilHHCZCGv0U0IW0ppnqqFfs70C15Z_w0HFa2BDlb49ah2eDxdYtUYPJ4tCcMlaDhE53F_4xobYgfPwVgVIeBpDLjfOA-fdgON1XhY16Ajtg2eWw3JBji6pC3BHHW0rjmNJm4PLsSUqf9iSvhQ3pASdklq8AiSvtncoqta7QLc_fc2Wo2Gq8GEzBbj6aA_IzrPJBEgKTNr0ctzsRYZ1YVSps67XNUy1zQrZC_PaIIkS7szybu6VoqCEBqgy3PRRg9n7cG79yOEWG3d0TcpseIZK7Iu41wm6vFMae9C8FBXB2_3yn9VjFanF1SnF1TpqNWiFL-qZnc8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419451227</pqid></control><display><type>article</type><title>142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>COSGROVE, RICHARD ; ANTONELLIS, MEGHAN P. ; DROZ, BRIAN ; ROELL, WILLIAM C. ; SLOOP, KYLE ; MOYERS, JULIE ; COGHLAN, MATTHEW P. ; EMMERSON, PAUL ; COSKUN, TAMER ; SAMMS, RICARDO J.</creator><creatorcontrib>COSGROVE, RICHARD ; ANTONELLIS, MEGHAN P. ; DROZ, BRIAN ; ROELL, WILLIAM C. ; SLOOP, KYLE ; MOYERS, JULIE ; COGHLAN, MATTHEW P. ; EMMERSON, PAUL ; COSKUN, TAMER ; SAMMS, RICARDO J.</creatorcontrib><description>Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in type 2 diabetes mellitus (T2DM) patients. Preclinical data indicate that TZP lowers body weight due to a reduction in caloric intake; however, associated effects on feeding behavior have not been studied. To investigate how TZP affects homeostatic feeding, we examined its effect on markers of satiation (meal size), satiety (meal frequency) and hunger (time-interval between meals) in obese mice. Chronic treatment with TZP dose-dependently lowered body weight and food intake in high-fat fed mice. This reduction in total daily caloric intake was underlined by a reduction in meal size and frequency throughout a 14-day treatment period. Indicating that TZP’s effect on total energy intake is associated with reduced hunger and increased satiety. One driver of the current obesity epidemic is the consumption of highly palatable/calorically dense foods. To determine whether the anorexigenic action of TZP is associated with reward-related feeding, we exposed lean and obese mice to two-choice diet paradigms ((low-fat (6% of kcal from fat) vs. high-fat (40% or 60% of kcal from fat) diets). Importantly, we found that while TZP decreased total calories consumed, it also altered macronutrient preference by increasing the intake of a low-fat diet and reducing intake of a high-fat diet. Furthermore, when exposed to a series of two-choice bottle tests, TZP reduced the consumption of nutritive (fructose and sucrose) and non-nutritive (sucralose) tastants, suggesting that TZP’s anorexigenic action may be linked to the taste and caloric content of food. Taken together, these data indicate that TZP’s ability to lower daily energy intake is mediated by both a reduction in homeostatic and reward-driven food intake.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db20-142-OR</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Agonists ; Antidiabetics ; Body weight ; Body weight loss ; Calories ; Diabetes mellitus (non-insulin dependent) ; Diet ; Energy intake ; Feeding behavior ; Food intake ; Fructose ; High fat diet ; Hunger ; Low fat diet ; Nutrient deficiency ; Obesity ; Reinforcement ; Satiety ; Sucralose ; Sucrose ; Tastants</subject><ispartof>Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 1, 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>COSGROVE, RICHARD</creatorcontrib><creatorcontrib>ANTONELLIS, MEGHAN P.</creatorcontrib><creatorcontrib>DROZ, BRIAN</creatorcontrib><creatorcontrib>ROELL, WILLIAM C.</creatorcontrib><creatorcontrib>SLOOP, KYLE</creatorcontrib><creatorcontrib>MOYERS, JULIE</creatorcontrib><creatorcontrib>COGHLAN, MATTHEW P.</creatorcontrib><creatorcontrib>EMMERSON, PAUL</creatorcontrib><creatorcontrib>COSKUN, TAMER</creatorcontrib><creatorcontrib>SAMMS, RICARDO J.</creatorcontrib><title>142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding</title><title>Diabetes (New York, N.Y.)</title><description>Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in type 2 diabetes mellitus (T2DM) patients. Preclinical data indicate that TZP lowers body weight due to a reduction in caloric intake; however, associated effects on feeding behavior have not been studied. To investigate how TZP affects homeostatic feeding, we examined its effect on markers of satiation (meal size), satiety (meal frequency) and hunger (time-interval between meals) in obese mice. Chronic treatment with TZP dose-dependently lowered body weight and food intake in high-fat fed mice. This reduction in total daily caloric intake was underlined by a reduction in meal size and frequency throughout a 14-day treatment period. Indicating that TZP’s effect on total energy intake is associated with reduced hunger and increased satiety. One driver of the current obesity epidemic is the consumption of highly palatable/calorically dense foods. To determine whether the anorexigenic action of TZP is associated with reward-related feeding, we exposed lean and obese mice to two-choice diet paradigms ((low-fat (6% of kcal from fat) vs. high-fat (40% or 60% of kcal from fat) diets). Importantly, we found that while TZP decreased total calories consumed, it also altered macronutrient preference by increasing the intake of a low-fat diet and reducing intake of a high-fat diet. Furthermore, when exposed to a series of two-choice bottle tests, TZP reduced the consumption of nutritive (fructose and sucrose) and non-nutritive (sucralose) tastants, suggesting that TZP’s anorexigenic action may be linked to the taste and caloric content of food. Taken together, these data indicate that TZP’s ability to lower daily energy intake is mediated by both a reduction in homeostatic and reward-driven food intake.</description><subject>Agonists</subject><subject>Antidiabetics</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Calories</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diet</subject><subject>Energy intake</subject><subject>Feeding behavior</subject><subject>Food intake</subject><subject>Fructose</subject><subject>High fat diet</subject><subject>Hunger</subject><subject>Low fat diet</subject><subject>Nutrient deficiency</subject><subject>Obesity</subject><subject>Reinforcement</subject><subject>Satiety</subject><subject>Sucralose</subject><subject>Sucrose</subject><subject>Tastants</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNotkU1PAjEQhhujiYie_ANNPEq1H8uW9UaQrwQC2XDwtintLCmBLbYlfvwb_6lFzBzmME-eNzOD0D2jT1wI-WzWnBKWcbIoL1CLFaIggsu3S9SilHHCZCGv0U0IW0ppnqqFfs70C15Z_w0HFa2BDlb49ah2eDxdYtUYPJ4tCcMlaDhE53F_4xobYgfPwVgVIeBpDLjfOA-fdgON1XhY16Ajtg2eWw3JBji6pC3BHHW0rjmNJm4PLsSUqf9iSvhQ3pASdklq8AiSvtncoqta7QLc_fc2Wo2Gq8GEzBbj6aA_IzrPJBEgKTNr0ctzsRYZ1YVSps67XNUy1zQrZC_PaIIkS7szybu6VoqCEBqgy3PRRg9n7cG79yOEWG3d0TcpseIZK7Iu41wm6vFMae9C8FBXB2_3yn9VjFanF1SnF1TpqNWiFL-qZnc8</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>COSGROVE, RICHARD</creator><creator>ANTONELLIS, MEGHAN P.</creator><creator>DROZ, BRIAN</creator><creator>ROELL, WILLIAM C.</creator><creator>SLOOP, KYLE</creator><creator>MOYERS, JULIE</creator><creator>COGHLAN, MATTHEW P.</creator><creator>EMMERSON, PAUL</creator><creator>COSKUN, TAMER</creator><creator>SAMMS, RICARDO J.</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20200601</creationdate><title>142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding</title><author>COSGROVE, RICHARD ; ANTONELLIS, MEGHAN P. ; DROZ, BRIAN ; ROELL, WILLIAM C. ; SLOOP, KYLE ; MOYERS, JULIE ; COGHLAN, MATTHEW P. ; EMMERSON, PAUL ; COSKUN, TAMER ; SAMMS, RICARDO J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c647-3e701db38663b340c9aadf652af76c04978640e70710001725cfaa0e33cee5263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Agonists</topic><topic>Antidiabetics</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Calories</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diet</topic><topic>Energy intake</topic><topic>Feeding behavior</topic><topic>Food intake</topic><topic>Fructose</topic><topic>High fat diet</topic><topic>Hunger</topic><topic>Low fat diet</topic><topic>Nutrient deficiency</topic><topic>Obesity</topic><topic>Reinforcement</topic><topic>Satiety</topic><topic>Sucralose</topic><topic>Sucrose</topic><topic>Tastants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>COSGROVE, RICHARD</creatorcontrib><creatorcontrib>ANTONELLIS, MEGHAN P.</creatorcontrib><creatorcontrib>DROZ, BRIAN</creatorcontrib><creatorcontrib>ROELL, WILLIAM C.</creatorcontrib><creatorcontrib>SLOOP, KYLE</creatorcontrib><creatorcontrib>MOYERS, JULIE</creatorcontrib><creatorcontrib>COGHLAN, MATTHEW P.</creatorcontrib><creatorcontrib>EMMERSON, PAUL</creatorcontrib><creatorcontrib>COSKUN, TAMER</creatorcontrib><creatorcontrib>SAMMS, RICARDO J.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>COSGROVE, RICHARD</au><au>ANTONELLIS, MEGHAN P.</au><au>DROZ, BRIAN</au><au>ROELL, WILLIAM C.</au><au>SLOOP, KYLE</au><au>MOYERS, JULIE</au><au>COGHLAN, MATTHEW P.</au><au>EMMERSON, PAUL</au><au>COSKUN, TAMER</au><au>SAMMS, RICARDO J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2020-06-01</date><risdate>2020</risdate><volume>69</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in type 2 diabetes mellitus (T2DM) patients. Preclinical data indicate that TZP lowers body weight due to a reduction in caloric intake; however, associated effects on feeding behavior have not been studied. To investigate how TZP affects homeostatic feeding, we examined its effect on markers of satiation (meal size), satiety (meal frequency) and hunger (time-interval between meals) in obese mice. Chronic treatment with TZP dose-dependently lowered body weight and food intake in high-fat fed mice. This reduction in total daily caloric intake was underlined by a reduction in meal size and frequency throughout a 14-day treatment period. Indicating that TZP’s effect on total energy intake is associated with reduced hunger and increased satiety. One driver of the current obesity epidemic is the consumption of highly palatable/calorically dense foods. To determine whether the anorexigenic action of TZP is associated with reward-related feeding, we exposed lean and obese mice to two-choice diet paradigms ((low-fat (6% of kcal from fat) vs. high-fat (40% or 60% of kcal from fat) diets). Importantly, we found that while TZP decreased total calories consumed, it also altered macronutrient preference by increasing the intake of a low-fat diet and reducing intake of a high-fat diet. Furthermore, when exposed to a series of two-choice bottle tests, TZP reduced the consumption of nutritive (fructose and sucrose) and non-nutritive (sucralose) tastants, suggesting that TZP’s anorexigenic action may be linked to the taste and caloric content of food. Taken together, these data indicate that TZP’s ability to lower daily energy intake is mediated by both a reduction in homeostatic and reward-driven food intake.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db20-142-OR</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)
issn 0012-1797
1939-327X
language eng
recordid cdi_proquest_journals_2419451227
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Agonists
Antidiabetics
Body weight
Body weight loss
Calories
Diabetes mellitus (non-insulin dependent)
Diet
Energy intake
Feeding behavior
Food intake
Fructose
High fat diet
Hunger
Low fat diet
Nutrient deficiency
Obesity
Reinforcement
Satiety
Sucralose
Sucrose
Tastants
title 142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T23%3A21%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=142-OR:%20Tirzepatide,%20a%20Dual%20GIP%20and%20GLP-1%20Receptor%20Agonist,%20Mediates%20Its%20Anorexigenic%20Effect%20in%20Mice%20Due%20to%20a%20Reduction%20in%20Homeostatic%20and%20Reward-Related%20Feeding&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=COSGROVE,%20RICHARD&rft.date=2020-06-01&rft.volume=69&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db20-142-OR&rft_dat=%3Cproquest_cross%3E2419451227%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2419451227&rft_id=info:pmid/&rfr_iscdi=true